Healthcare Financial News

Subscribe to enjoy similar stories. The National Board of Examinations in Medical Sciences (NBEMS) last week launched its artificial intelligence (AI) training program for postgraduate medical students and faculty across all government and private medical colleges. The program, which received an overwhelming response of more than 50,000 confirmed early registrations, connects clinical knowledge with data science, preparing future healthcare leaders to effectively manage AI solutions in real-world settings.

Subscribe to enjoy similar stories. Mumbai: Tata Capital Healthcare Fund-backed Linux Laboratories, which is focused on central nervous system (CNS)-based domestic formulations, has appointed Avendus as an adviser to facilitate a capital raise, two people familiar with the matter said. The Chennai-based company aims to raise $50-70 million to fund its expansion plans through organic and inorganic growth, double down on its existing categories and widen its footprint beyond India, the people said on the condition of anonymity.

Subscribe to enjoy similar stories. Mumbai: InvAscent-backed Ankura Hospitals has kickstarted a fundraising process to raise ₹400-500 crore in a mix of primary and secondary transactions, three people familiar with the matter said. The Hyderabad-based company has appointed Alvarez & Marsal as an advisor to facilitate the capital raise, and the deal is expected to be launched in the coming weeks, the people said.

Subscribe to enjoy similar stories. New Delhi: India’s National Board of Examinations in Medical Sciences (NBEMS) on 13 January lowered the qualifying cut-off marks for the National Eligibility-cum-Entrance Test for Postgraduate (NEET-PG) 2025 in a bid to fill vacant postgraduate medical seats.

Subscribe to enjoy similar stories. Mumbai: Faridabad-based Medsource Ozone Biomedicals, an in-vitro diagnostics instruments and reagents manufacturer, has hired the Big 4 audit firm Ernst & Young as an advisor to explore capital-raising options to fund its expansion, said two people familiar with the matter. “The company may look to raise about ₹300-400 crore, and the promoters may liquidate some stake for the incoming investor," one of the people cited above said.

Subscribe to enjoy similar stories. Imagine Reinhold Messner reaching the summit of Everest only to look back at the trail of climbers behind him, and thinking: I’m going to go a little further. With that, he leaps off the top of the highest peak in the world into the vast, icy vacuum below.

Subscribe to enjoy similar stories. As India’s pharmaceutical sector kicks off its earnings season for the quarter ended December on Friday, analysts expect muted margins. A key reason for this is the loss of patent exclusivity for the blood cancer drug Revlimid in the US.

Subscribe to enjoy similar stories. New Delhi: With over 18,000 postgraduate medical seats vacant and hospitals facing a shortage of specialists, the National Board of Examinations in Medical Sciences (NBEMS) has moved to prevent a costly waste of training capacity.

Subscribe to enjoy similar stories. MUMBAI : As most credit card issuers chase premium experiences and luxury rewards to drive higher spending, BoB Card is betting on healthcare, wellness and insurance-led benefits to carve a niche for itself. With rising medical costs and changing customer preferences reshaping how credit cards are used, the Bank of Baroda subsidiary is moving away from one-size-fits-all offerings towards cohort-specific products.

Subscribe to enjoy similar stories. On 7-8 January, OpenAI rolled out two healthcare products: ChatGPT Health for users and ChatGPT for Healthcare, for organizations in the industry. While ChatGPT Health is an extension of the existing chatbot, offering a space dedicated for health, the latter aims to automate workflows for healthcare organizations, a niche where Indian healthtech firms have attracted investor interest.

At first glance, this may seem like a question for economists and statisticians, a matter of compensation data, actuarial logic and policy benchmarks. It is nothing of the sort. It is a moral question that we in India must ask ourselves.As a citizen who has lived his entire life in India’s metropolitan cities, benefited from a measure of material success and travelled globally, my conclusion is neither emotional nor ideological.

₹3,500–4,000 crore with existing investor Lighthouse Funds and the promoters set to offload a total of about 60% of their holding,” one of the people cited above said. A second person confirmed the details, adding that this will largely be a secondary transaction.This assumes significance as fast-growing, consumer-facing healthcare companies are attracting strong investor interest, backed by rising insurance penetration, improving affordability and a widening patient base in India’s medical devices sector.In August, Mint first reported that the company had reopened talks and appointed O3 Capital to help with the mandate after discussions with Temasek for a significant minority stake were put on hold in 2024.Tynor’s founder Pushvinder Jit Singh, Lighthouse Funds, Kedaara and O3 Capital did not respond to emails sent on Tuesday.In 2024, Mint had exclusively reported that Singapore-based Temasek was the front-runner to acquire a significant minority stake in the company, outpacing other global private equity firms such as Warburg Pincus and Norwest Venture Partners.The new development comes nearly eight years after Tynor raised $21 million at a post-money valuation of $103.3 million from investors including Lighthouse, Thuasne and Vihome B.V.

₹500 crore in revenue and forming the backbone of its sales—such as Dabur Red Paste, Dabur Amla hair oil, Dabur Honey and Chyawanprash, are widely perceived as “boomer brands,” Mahasuar said.“Gen Z is very particular about ingredients, and look and feel—and most importantly they want visible results,” he told Mint. “Companies in skin care and hair care have been struggling over the last three to four years.

diabetes burden of 100 million after China, and another 136 million in the pre-diabetes stage. A high sugar intake is associated with type-2 diabetes, cardiovascular disease, obesity and other metabolic health risks.Until the covid-19 pandemic, sugar consumption grew at an annual rate of about 4.1%, said Prakash P.

lawsuits were filed in the last week of December by individuals in states including Arizona and California, who claimed they lost sensitive personal data such as financial account details, social security numbers, and addresses. Mint could not independently ascertain whether Cognizant intends to settle the claims.The 23 December complaint alleged that Cognizant did not disclose critical details of the cyberattack.“Defendants (Cognizant) have not disclosed the details of the cyberattack to Plaintiffs (complainants) or Class members, including the root cause of the data breach, the vulnerabilities exploited, and the remedial measures undertaken to ensure such a breach does not occur again.

Indian stock markets: The Indian stock market ended largely flat on Tuesday, 30 December, as investors stayed cautious amid a lack of fresh domestic triggers and mixed global cues. The Sensex closed at 84,675.08, down 20 points, or 0.02%, while the Nifty 50 slipped 3 points, or 0.01%, to 25,938.85.

₹14.5 lakh in the pre-GST phase to nearly ₹19 lakh post the reform. This increase reflected a deliberate reassessment of adequacy rather than incremental upgrades.For years, health covers priced below ₹10 lakh have dominated new purchases, largely due to price sensitivity and a limited understanding of hospital costs.

all-stock deal will bring Advent and Warburg Pincus onto Coforge’s board, a move that could bolster its fundraising prospects. Coforge will issue shares worth $1.89 billion to Encora’s shareholders at ₹1,815 apiece, and may raise about $550 million through a qualified institutional placement or a bridge loan to retire Encora’s term debt.The deal—India’s largest ever in IT services—could lift Coforge’s FY27 revenue by 28%, according to Jefferies India.

Dear reader, as 2025, a year of global tumult and volatility, rolls by, Mint's reporters and columnists look around the corner on what is coming in 2026—to help you know what to expect and prepare for it. Tell us what you think at [email protected] DELHI: India is pushing to upgrade its image from the 'pharmacy of the world' to a global life sciences hub, a goal that faces critical execution risks, especially concerning quality standards and policy follow-through.

New Delhi: To reduce India’s high burn-related mortality rates and standardise care across hospitals, the Centre has issued comprehensive treatment guidelines that formalise first-aid practices and discourage the use of common household remedies, according to two officials and a document seen by Mint.The development assumes significance given the rising burn injuries—an estimated 6-7 million injuries annually and around 150,000 deaths each year—with women and children disproportionately affected due to cooking fires and flammable liquids.The new framework, to be adopted by health centres with immediate effect, seeks to replace India’s fragmented, hospital-specific burn care protocols with a uniform, evidence-based system ranging from first responders, primary health centres (PHCs) and tertiary hospitals.The guidelines organise burn care into four levels—pre-hospital, primary, secondary and tertiary—clearly outlining responsibilities at each stage to reduce delays, inappropriate treatment and avoidable complications.They address a critical gap where healthcare professionals often relied on a mix of personal expertise and conflicting protocols due to resource constraints.The effectiveness of burn care in India has been constrained by chronic shortages of trained personnel, essential supplies and specialised equipment, gaps that are most acute in resource-limited settings, impacting patient recovery and complication rates."Standard treatment guidelines are vital because medical science is evidence-based, yet currently, individual hospitals often follow disparate protocols. It is crucial to collate best practices to ensure uniformity," said Dr.

Smartwatches are getting smarter – at least, health-wise.These devices, so far largely considered lifestyle accessories with basic fitness-tracking features mostly shunned by medical practitioners, are increasingly receiving medical certifications from the Centre—making them health devices that alert users against issues such as heart rate fluctuations, sleep disorders and blood pressure anomalies.On 4 December, Apple launched hypertension tracking on its latest Apple Watch Series 11 smartwatch. While the feature does not give a direct blood pressure readout, it monitors a user’s blood oxygen, stress levels and other heart-related parameters to notify them that they may have a potential hypertension issue.The company received government approval to offer this clinical-grade feature in late November, a person aware of the development told Mint, making it only the second consumer-grade smartwatch until now to be approved by New Delhi.Hypertension implies high blood pressure, a condition that potentially damages heart tissues in the long run.